Targeting the RyR2 to Prevent Atrial Fibrillation

Circ Arrhythm Electrophysiol. 2022 Oct;15(10):e011514. doi: 10.1161/CIRCEP.122.011514. Epub 2022 Sep 30.

Authors

Anne M Gillis¹, Dobromir Dobrev^{2

3

4}

Affiliations

¹ Department of Cardiac Sciences, University of Calgary and Libin Cardiovascular Institute, Alberta, Canada (A.M.G.).
² Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Germany (D.D.).
³ Department of Medicine, Montreal Heart Institute and Université de Montréal, Montréal, Canada (D.D.).
⁴ Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX (D.D.).

No abstract available

Keywords: Editorials; antiarrhythmic drugs; atrial fibrillation; morbidity; risk; sarcoplasmic reticulum.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anti-Arrhythmia Agents
Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / prevention & control
Calcium / metabolism
Humans
Ryanodine Receptor Calcium Release Channel* / genetics
Sarcoplasmic Reticulum / metabolism

Substances

Ryanodine Receptor Calcium Release Channel
Anti-Arrhythmia Agents
Calcium

Grants and funding